Mr. Jonathan Rigby reports

SERNOVA APPOINTS DAVID PATERSON PH.D. TO ITS BOARD OF DIRECTORS

Dr. David Paterson, PhD, will join Sernova Corp.'s board of directors, effective immediately.

"I am pleased to have been able to attract David Paterson's significant talent to Sernova's board of directors," said Jonathan Rigby, president and chief executive officer of Sernova. "Mr. Paterson brings more than 30 years of biotech experience with substantial contributions as a senior executive, board member and founder of numerous companies, with a focus on corporate and business development, intellectual property generation and prosecution, and alliance management."

Dr. Paterson is currently employed at Colorado State University as assistant vice-president of research translation and commercialization, where he manages strategic industry relationships. In addition, he brings broad biopharmaceutical industry knowledge, having worked for Impax Laboratories in both Europe and North America, where he provided leadership and board support to the business development team for 10 years until its acquisition by Amneal Pharmaceuticals. Prior to Impax, Dr. Paterson held senior roles with Sepracor (Sunovion), GlaxoSmithKline and Skyepharma. Dr. Paterson is also a co-founder of Neurogastrx Inc., helping to bring in early-stage capital. Dr. Paterson has a bachelor of science degree from the University of Glasgow, a PhD from the University of Illinois, and was a postdoctoral fellow in molecular genetics and cellular biology at the University of Chicago.

"I am very excited to be joining the board of Sernova and offer up my scope of expertise to help the company grow and prosper within the Type 1 diabetes space, and to help open doors to new collaborations and further establish the Cell Pouch transplantation system as a top-tier technology within the regenerative medicine cell therapy sector," said Dr. Paterson.

About Sernova Corp.

Sernova is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease and blood disorders that include hemophilia A. Sernova is currently focused on developing a "functional cure" for insulin-dependent diabetes with its lead technology, the Cell Pouch system, a novel implantable and scalable medical device with immune-protected therapeutic cells.

On implantation, the Cell Pouch forms a natural, vascularized tissue environment in the body for long-term survival and function of therapeutic cells that release essential factors that are absent or deficient in patients with certain chronic diseases. Sernova's Cell Pouch has demonstrated its potential to be a functional cure for people with Type 1 diabetes in a continuing phase 1/2 clinical study at the University of Chicago.

Sernova is collaborating with Evotec to develop an implantable, off-the-shelf, iPSC-based (induced pluripotent stem cell) islet replacement therapy. This partnership is expected to provide Sernova a potentially unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (Type 1 and Type 2). Sernova's Cell Pouch development pipeline also includes a cell therapy for hypothyroid disease resulting from thyroid gland removal, and an ex vivo lentiviral Factor VIII gene therapy for hemophilia A.

We seek Safe Harbor.